Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMOP Regimen and Chidamide in Newly Diagnosed PTCL
NCT05896813Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2023
- Primary completion
- Jan 2025
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Open-label, single-arm trial of tucidinostat and mitoxantrone in peripheral T-cell lymphoma (PTCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
tucidinostatmitoxantrone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT05896813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896813.